Use of BRAF inhibitors was shown to enhance the immunogenicity of Melanoma without negatively effecting T-cell function [171,172] possibly through increases in HLA expression [173], however, other studies observed reduced TIL in BRAF treated tumour models [174]. This evidence concerns the gene BRAF and melanoma.